Note: All changes are versus the prior-year period unless otherwise stated
"We witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of COVID-19 products," remarked managing director Dilip Shanghvi, with "growth across all our businesses." Sun Pharma's shares climbed as much as 10% on the results.
The executive noted that the company's India business "continues to do well, while our global specialty revenues have grown over Q4." Shanghvi added "we are happy with Ilumya's performance, which has grown both [year-on-year] and sequentially."
To read more Top Story articles, click here.